Cover Image

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they d...

Full description

Saved in:
Bibliographic Details
Main Authors: Kiladjianm, Jean-Jacques (Author) , Marin, Francisca Ferrer (Author) , Al-Ali, Haifa Kathrin (Author) , Alvarez-Larrán, Alberto (Author) , Beggiato, Eloise (Author) , Bieniaszewska, Maria (Author) , Breccia, Massimo (Author) , Buxhofer-Ausch, Veronika (Author) , Cerna, Olga (Author) , Crisan, Ana-Manuela (Author) , Reiter, Andreas (Author)
Format: Article (Journal)
Language:English
Published: 4 March 2024
In: Annals of hematology
Year: 2024, Volume: 103, Issue: 7, Pages: 2299-2310
ISSN:1432-0584
DOI:10.1007/s00277-024-05665-4
Online Access:Resolving-System, kostenfrei, Volltext: https://doi.org/10.1007/s00277-024-05665-4
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00277-024-05665-4
Resolving-System, kostenfrei: https://doi.org/10.25673/117314
Get full text
Author Notes:Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, et al. ; authors and affiliations: Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer-Ausch, Olga Cerna, Ana-Manuela Crisan, Andreas Johannes Reiter [und viele weitere]
Description
Summary:Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they do not modify the natural history of the disease and hence, have no impact on disease progression. Ropeginterferon alfa-2b (trade name BESREMi®), a novel, monopegylated interferon alfa-2b with an extended administration interval, has demonstrated a robust and sustained efficacy in polycythemia vera (PV) patients. Given the similarities in disease pathophysiology and treatment goals, ropeginterferon alfa-2b holds promise as a treatment option for ET. The ROP-ET trial is a prospective, multicenter, single-arm phase III study that includes patients with ET who are intolerant or resistant to, and/or are ineligible for current therapies, such as hydroxyurea (HU), anagrelide (ANA), busulfan (BUS) and pipobroman, leaving these patients with limited treatment options. The primary endpoint is a composite response of hematologic parameters and disease-related symptoms, according to modified European LeukemiaNet (ELN) criteria. Secondary endpoints include improvements in symptoms and quality of life, molecular response and the safety profile of ropeginterferon alfa-2b. Over a 3-year period the trial assesses longer term outcomes, particularly the effects on allele burden and clinical outcomes, such as disease-related symptoms, vascular events and disease progression. No prospective clinical trial data exist for ropeginterferon alfa-2b in the planned ET study population and this study will provide new findings that may contribute to advancing the treatment landscape for ET patients with limited alternatives.
Item Description:Gesehen am 15.10.2024
Physical Description:Online Resource
ISSN:1432-0584
DOI:10.1007/s00277-024-05665-4

Similar Items